Pure Global
NCT06102083

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

A Phase II, Multi-center, Randomized, Double-blinded, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of TDI01 Suspension for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Beijing Tide Pharmaceutical Co., Ltd·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention
TDI01 suspension
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing Tide Pharmaceutical Co., Ltd
Timeline & enrollment
Phase
Phase 2
Start date
Nov 02, 2023
End date
Mar 01, 2026
Enrollment
120 participants
Primary outcome

Change From Baseline in Forced Vital Capacity (FVC) (mL) at Week 24

Summary

This trial was performed in patients with idiopathic pulmonary fibrosis (IPF) to evaluate the
 clinical efficacy and safety of different doses of TDI01 Suspension, compared with control,
 for the treatment of patients with IPF.

ICD-10 classifications
Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06102083
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06102083 through Pure Global AI's free database. This Phase 2 trial is sponsored by Beijing Tide Pharmaceutical Co., Ltd and is currently Not yet recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.